LG, Clarke WR, Berl T, Pohl MA, Lewis JB, alternatives to avapro E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect alternatives to avapro the angiotensin-receptor antagonist irbesartan in alternatives to avapro with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian.

number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & alternatives to avapro dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the reduction of renal disease progression in patients with nephropathy due to alternatives to avapro 2 alternatives to avapro N Engl J Med alternatives to avapro (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3 IrbesartanFrom Wikipedia, alternatives to avapro free encyclopedia(Redirected from Avapro)Jump to: navigation, searchIrbesartanSystematic (IUPAC) alternatives to avapro number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical.

life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal.